Please ensure Javascript is enabled for purposes of website accessibility

Why Biogen Shares Soared Today

By Keith Speights - Updated Feb 10, 2020 at 10:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A favorable patent ruling could translate to smoother sailing for Biogen's top-selling drug.

What happened

Shares of Biogen (BIIB -0.09%) were soaring 17.2% as of 2:59 p.m. EST on Wednesday after rising as much as 32.4% earlier in the afternoon. The big gain came on news that the Patent Trial and Appeal Board (PTAB) ruled in favor of Biogen in a challenge by Mylan (MYL) to the biotech's key patent for multiple sclerosis drug Tecfidera.

So what

Tecfidera ranks as Biogen's top-selling product. The drug generated $4.4 billion in sales in 2019, accounting for nearly one-third of Biogen's total revenue. 

Stamp next to stamp marking stating "protected" beneath the word "patent"

Image source: Getty Images.

Mylan filed a petition with the PTAB in July 2018 challenging the validity of a key Biogen patent for Tecfidera. Japanese drugmaker Sawai Pharmaceutical and its U.S. subsidiary, Sawai USA, later joined Mylan in its patent challenge. Had the PTAB decided against Biogen, its revenue from Tecfidera would have been at risk.

The challenges to Tecfidera aren't over yet, though. Biogen is also involved in patent litigation with 22 other drugmakers seeking to develop generic versions of the drug. Biogen lost in a U.S. District Court lawsuit against Banner Life Sciences last month and is also scheduled to go to trial with Mylan in a U.S. District Court this month.

Now what

Investors will want to closely watch what happens with the remaining court cases related to Biogen's Tecfidera patent. It's definitely encouraging for the company, though, that it won its argument with the PTAB.

But the biggest thing to keep your eyes on with any biotech stock is its pipeline progress. Biogen should soon file for Food and Drug Administration approval of experimental Alzheimer's disease drug aducanumab. Should the company win a green light to market the drug, today's gain could seem small in comparison with how much Biogen stock could skyrocket.

Editor's note: A previous version of this article stated that Biogen's lawsuit with Banner Life Sciences was scheduled to go to court in February. The case actually began in January with Banner winning the lawsuit. The Fool regrets the error.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
$202.36 (-0.09%) $0.18
Viatris Inc. Stock Quote
Viatris Inc.
Banner Corporation Stock Quote
Banner Corporation
$56.30 (0.81%) $0.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.